创业板指早盘涨幅扩大至1%，上证指数现涨0.37%；托育服务、创新药、短剧互动游戏、水泥建材、可 控核聚变等概念走高，保险、稀土永磁、光刻机（胶）等概念跌幅居前；全市约3000股上涨，2100股下 跌，主力资金净流出超110亿元。 ...

Group 1 - The concepts of CRO, weight loss drugs, and innovative drugs are experiencing a resurgence in the market [1] - Companies such as Puris, which saw a rise of over 14%, and Jizhitang, which hit the daily limit, are leading this trend [1] - Other companies like Saily Medical, Shanghai Yizhong, Yinuosi, and Aosaikan are also witnessing significant gains [1]

Core Viewpoint - The innovative drug sector experienced a rebound, with CXO direction leading the gains, as several companies saw significant stock price increases, indicating growing confidence in China's innovative drug capabilities on the international stage [1] Group 1: Market Performance - Companies such as Puris, Medici, Jiuzhitang, Sali Medical, Huanyu Pharmaceutical, and Shanghai Yizhong all reported stock price increases, with Puris rising over 10% and others exceeding 6% [1] Group 2: Industry Insights - CICC released a report highlighting that the recent disclosures of numerous clinical data at ASCO, along with significant business development (BD) deals represented by Sanofi, further confirm the international competitiveness of Chinese innovative drugs [1] - The upcoming ESMO conference and the data disclosures surrounding it are expected to positively catalyze the innovative drug sector [1]

A股大医药概念集体回升，重组蛋白、CRO、生物制品、创新药等概念跌幅均有收窄；锦波生物涨超 3%，上海莱士、万泰生物、毕得医药等个股跟涨。特朗普此前宣布，药品关税可能高达200%。 ...

Core Insights - The report indicates that the current market sentiment is at a high level, with a score of 88, categorizing it as "overheated" [6][10][22] - Recent policy support and improved market sentiment have contributed to a bullish trend in the market [10] Market Themes Tracking - **Data Theme**: The National Data Bureau and the State Administration for Market Regulation have introduced measures to enhance data circulation efficiency, potentially increasing efficiency by 30% [7] - **Cross-Border Payment Theme**: The People's Bank of China has released a draft for the rules governing the Renminbi cross-border payment system, aiming to simplify participation conditions for foreign institutions [7] - **Innovative Drug Theme**: The National Healthcare Security Administration and the National Health Commission have issued measures to support the high-quality development of innovative drugs, emphasizing the use of medical insurance data for drug research [7] Major Capital Inflows - The report lists the top ten stocks with significant net inflows, including Zhongyou Capital (90.12 million), Pengding Holdings (64.11 million), and others [11][12] Major Capital Outflows - The report also highlights the top ten stocks with significant net outflows, such as Changshan Pharmaceutical (-83.03 million) and Jinyi Culture (-79.62 million) [13][23] Financing and Margin Trading - The report provides insights into financing net purchases and margin trading, indicating investor sentiment towards specific stocks and sectors [23]

CAR-T（一种细胞治疗药物）、ADC（抗体偶联药物）……对于这些创新药，患者翘首企盼。然 而，一些创新药获批上市后仍难用上。 创新药研发成本高，有的定价高达百万元，患者负担不起，还有的创新药获批后在医疗机构难买 到，创新药"用药难"问题成为焦点。 近日，多个支持创新药研发应用的文件密集出台，创新药迎来利好。创新药如何不再用药难？7月8 日，科技日报记者就此采访了多位专家。 一问：创新药定价如何降下来？ "创新药研发投入大、链条长、成功概率低，上市后定价相较于仿制药更高，有其合理性。"复旦大 学公共卫生学院教授刘宝告诉记者，目前国内上市的CAR-T产品，每针定价甚至高达129万元，即便未 来可能会有价格微调，但如果要普通家庭全部自己支付，是难以承受的。 "研发投入大，要想办法把它降下来。"刘宝说，临床试验是创新药上市前研发投入最大的环节之 一。为激励创新药研发，相关部门出台了一系列政策，通过附条件批准、优先审评审批等举措压缩研发 周期和审评时间，降低创新药研发成本。 例如，在优化创新药临床试验审评审批试点工作的基础上，国家药监局6月16日提出拟对三类创新 药的临床试验申请在30个工作日内完成审评审批。 为大幅 ...

其 他 报 告 2025年07月09日 晨会纪要 | 国内市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 上证综合指数 | 3497 | 0.70 | 1.40 | | 深证成份指数 | 10588 | 1.47 | 1.25 | | 沪深300指数 | 3998 | 0.84 | 1.54 | | 创业板指数 | 2181 | 2.39 | 1.50 | | 上证国债指数 | 226 | -0.02 | 0.16 | | 上证基金指数 | 6947 | 0.12 | 0.16 | | | | 资料来源:同花顺iFinD | | | 海外市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 中国香港恒生指数 | 24148 | 1.09 | -1.52 | | 中国香港国企指数 | 8709 | 1.16 | -1.75 | | 中国台湾加权指数 | 22362 | -0.30 | -0.14 | | 道琼斯指数 | 44406 | -0.9 ...

Core Viewpoint - Chinese innovative pharmaceuticals are accelerating their international expansion, with significant licensing deals and supportive policies facilitating this trend [2][6][7]. Group 1: Market Activity - In the first half of the year, the upfront payments for innovative drug licensing exceeded $2.5 billion, with total transaction amounts nearing $50 billion, almost matching the total for the previous year [2]. - A notable licensing agreement was signed between 3SBio and Pfizer, valued at up to $60.5 billion, involving the exclusive rights for the PD-1/VEGF bispecific antibody SSGJ-707 outside of mainland China [3]. - Rongchang Bio announced a licensing deal with Vor Biopharma Inc. with a total transaction value of $4.23 billion, including an upfront payment of $45 million [3]. Group 2: Policy Support - The rapid development of the innovative drug industry is supported by policy reforms, including expedited drug review processes and dynamic adjustments to the medical insurance catalog [6][7]. - In the first half of the year, 43 innovative drugs and 45 innovative medical devices were approved, representing year-on-year increases of 59% and 87%, respectively [6]. - Recent measures have been introduced to support the internationalization of innovative drugs, encouraging companies to explore markets in Southeast Asia and Central Asia [7]. Group 3: Industry Trends - The internationalization strategies of Chinese pharmaceutical companies are diversifying, with four main models identified: independent internationalization, licensing, NewCo model, and mergers and acquisitions [5]. - The collaboration landscape is broadening, with partnerships not only with traditional pharmaceutical companies but also with emerging biotech firms [4]. - Despite the progress, challenges remain, including weaknesses in basic research, target homogeneity, regulatory alignment, and commercialization capabilities [7].

而此次《若干措施》明确提出：要推动医保数据为创新药研发提供决策支撑；要运用药物经济学、卫生 技术评估等方法评估支付标准；要设立商业健康保险创新药目录，推动多层次保障体系联动。这些内容 表明，医保制度的角色正在发生深刻变化——从以控费为核心的"被动评估者"向"临床价值引导 者"与"创新资源协调者"转型。 特别是在合理确定医保支付标准方面，文件提出要综合考虑研发投入、市场竞争与临床需求，不再单一 以最低价格作为评估依据。医保谈判机制将更加专业、灵活和动态，为创新药企业留出可持续发展的空 间。 其次，从挂网采购到医保结算，创新路径得以全面提速。推动创新药真正进入临床、服务患者，关键不 仅在于政策许可，还在于操作路径的顺畅性。《若干措施》提出了包括"优化挂网程序""设立绿色通 道""鼓励设立特例单议"等一系列实操性强的措施，打通从医保谈判、药事会评审到医院采购与使用的 全流程障碍。 尤其值得注意的是：医保谈判药品和商业健康保险目录药品将不再受长期以来医疗机构"一品两规"限 制；医保定点医疗机构应在药品目录公布后3个月内召开药事会，及时完成配备与采购决策；对合理使 用创新药的特例病例，将支持采用项目付费等多样化支付方式 ...

创新药板块频出牛股，在北证表现如何？ 从板块/题材的角度悉数复盘上半年的行情，北研君发现不论北证还是沪深，创新药主题持续得到资金 热捧，当前处于第一波大行情暂歇、盘整期，又时值7月这个全年相对看重企业基本面的窗口，我们将 北交所创新药概念股盘点汇总如下。本文仅做梳理，不作为投资方向的建议，请各位粉丝前往小号翻 阅。 ...